Munich-based Twogee Biotech, a biotechnology start-up focused on enzyme-driven biomass conversion, has secured €2.16 million in seed funding to accelerate the commercial rollout of its circular bioeconomy platform. The round was backed by High-Tech Gründerfonds and Bayern Kapital, alongside strategic partners AgriFoodTech Venture Alliance and Heinz Entsorgung.
Founded in 2024 by biotech entrepreneur Frank Wallrapp and industrial biotechnology specialist Helge Jochens, Twogee Biotech develops customised enzyme solutions that enable industrial players to convert low-value biomass residues into sustainable, second-generation raw materials. The company is particularly focused on unlocking sugars for applications across bio-based chemicals and synthetic biology.
Turning waste streams into industrial feedstock
At the core of Twogee Biotech’s offering is a predictive development platform that combines enzyme screening, strain engineering and fermentation design. This integrated approach allows the company to tailor enzyme systems to specific biomass inputs, improving conversion efficiency while reducing development timelines and scale-up risk for industrial partners.
Many agricultural and industrial by-products remain underutilised despite containing significant economic potential. Twogee Biotech works with partners to access this value through solutions designed for straightforward integration into existing processes, supporting low-CO₂ and circular value creation.
According to CEO Frank Wallrapp, the company’s focus is on delivering commercially viable enzyme systems that can be deployed quickly and reliably. By shortening the path from laboratory development to industrial application, Twogee Biotech aims to make circular biomass utilisation both practical and profitable.
Commercial progress and licensing strategy
Twogee Biotech plans to use the newly raised capital to further develop its enzyme platform and advance commercialisation. The company has already completed initial minimum viable products and paid pilot projects with industrial partners, validating both the technical performance and commercial relevance of its approach.
The start-up intends to pursue a licensing-based business model, enabling customers to produce enzymes locally at their own sites. This decentralised production model is designed to lower costs, reduce emissions associated with transport, and support the development of resilient, circular chemical value chains.
Leadership and investor backing
Twogee Biotech is led by CEO and co-founder Frank Wallrapp, who brings experience in scaling biotechnology ventures and translating research into industrial applications. Co-founder Helge Jochens contributes deep technical expertise in enzyme engineering and fermentation processes, underpinning the company’s science-driven strategy.
The seed round marks Twogee Biotech’s first external financing since its formation in 2024 and provides the foundation for its next phase of growth. Backing from High-Tech Gründerfonds and Bayern Kapital adds institutional support from two of Germany’s most active early-stage investors, while strategic investors bring domain knowledge and access to industrial networks.
As pressure mounts on chemical and materials industries to decarbonise and reduce waste, Twogee Biotech is positioning itself at the intersection of industrial biotechnology and circular economy innovation. With fresh capital and early commercial traction, the company aims to play a growing role in transforming biomass residues into sustainable industrial feedstocks across Europe and beyond.
Also Read: daphni Blue Completes €260 Million Final Close to Back Science-Driven European Innovation